TITLE

Drotrecogin Alfa (Activated): A Viewpoint by Derek C. Angus

AUTHOR(S)
Angus, D.C.
PUB. DATE
February 2002
SOURCE
Drugs;2002, Vol. 62 Issue 4, p631
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Examines the efficacy of drotrecogin alfa in reducing the mortality of patients with severe sepsis. Role of endogenous activated protein C in sepsis; Benefits and adverse effect of drotrecogin alfa therapy; Limited data on patient-centered outcomes associated with therapy.
ACCESSION #
6280832

 

Related Articles

  • Gulf casualties to receive trial drug. Coghlan, Andy // New Scientist;2/23/91, Vol. 129 Issue 1757, p18 

    Reports on the results of clinical trials of the drug Centoxin, which combats severe blood poisoning or septicemia. U.S. Food and Drug Administration's (FDA) consideration of the drug valuable in the treatment of battlefield injuries; Stipulation that doctors in the Persian Gulf cannot...

  • Activated protein C was cost-effective for prolonging survival in a subgroup of patients with severe sepsis. Manns, B.J.; Lee, H.; Doig, C.J.; Johnson, D.; Donaldson, C.; Wiedemann, Herbert P. // ACP Journal Club;May/Jun2003, Vol. 138 Issue 3, p81 

    Summarizes a study that investigated whether treatment with recombinant human-activated protein C is more cost-effective than conventional care for prolonging survival in patients with severe sepsis. Characterization of the patients; Main cost and outcome measures; Results of the study.

  • Recombinant human activated protein C in severe sepsis. Mann, Henry J. // American Journal of Health-System Pharmacy;2/15/2002, Vol. 59 Issue 4, pS19 

    Protein C, a naturally occurring vitamin K-dependent serine protease in the blood, remains inactive until exposed to the thrombin-thrombomodulin complex. This change between the inactive and active forms occurs constantly in humans and serves to balance the coagulation cascade. APC functions in...

  • Fresh from the pipeline: Drotrecogin alpha (activated). Lebbos, John; Bradsher, Julia; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Jan2003, Vol. 2 Issue 1, p13 

    In November 2001, drotrecogin alpha (activated) (Xigris) became the first drug to be approved by the FDA for the treatment of severe sepsis, a systemic response to infection that kills an estimated 500,000 people each year. Xigris was widely anticipated to be a blockbuster, but it has not yet...

  • Activated Protein C for Sepsis. Mackenzie, Alasdair // New England Journal of Medicine;3/25/2010, Vol. 362 Issue 12, p1150 

    A letter to the editor is presented in response to the article "Activated Protein C for Sepsis," by S. Toussaint et al. published in the December 31, 2009 issue.

  • Activated Protein C for Sepsis. Toussaint, Susanne; Gerlach, Herwig // New England Journal of Medicine;3/25/2010, Vol. 362 Issue 12, p1150 

    A response by Susanne Toussaint and Herwig Gerlach to a letter to the editor about their article "Activated Protein C for Sepsis" in the December 31, 2009 issue is presented.

  • Managing high-cost biotechnology products. Wong, Dorothy H.; Yang, Peggy // American Journal of Health-System Pharmacy;6/15/2003, Vol. 60 Issue 12, p1213 

    Offers ways to ensure the appropriate use of Drotrecogin alfa, a recombinant human activated protein C with U.S. Food and Drug Administration-approved labeling for use in the treatment of severe sepsis in adult. Medication-related issues; Criteria for use; Medication-use evaluation to track...

  • Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis. Pastores, S.M. // Postgraduate Medical Journal;Jan2003, Vol. 79 Issue 927, p5 

    Recent studies have highlighted the close link between activation of the coagulation system and the inflammatory response in the pathophysiology of severe sepsis. The protein C anticoagulant pathway plays an integral part in modulating the coagulation and inflammatory responses to infection. In...

  • TREM-1: A new regulator of innate immunity in sepsis syndrome. Nathan, Carl; Ding, Aihao // Nature Medicine;May2001, Vol. 7 Issue 5, p530 

    Although we have drugs and biologics designed to interfere with the innate immune response, none has been shown to shut down the massive inflammatory reaction that occurs during sepsis. A new pro-inflammatory myeloid-cell receptor might make a better target.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics